Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
ULURU Inc. Business Update And Outlook
Date:3/18/2013
ADDISON, Texas, March 18, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today provided a business update and outlook for the balance of 2013.
The current focus of our business activities is on the expansion of our global commercialization of Altrazeal® in conjunction with Altrazeal Trading Ltd. Currently, Altrazeal Trading Ltd. is in the process of establishing a global network of sales and marketing partners with the necessary capabilities to maximize the market potential of Altrazeal®.
Based on the success achieved to-date establishing marketing partnerships, it is anticipated that by the end of the second quarter of 2013 initial product shipments will have been made to 5-6 international sales partners.
Commenting on the international commercialization of Altrazeal®, Helmut Kerschbaumer , Managing Director of Altrazeal Trading Ltd., stated, "With the extensive clinical experience in Europe and Australia, supported by the data previously generated in the United States we have developed significant interest from potential sales and marketing partners in many European markets, including Eastern Europe, Turkey, the Middle East, the Indian subcontinent and South Africa. We are now in the very favorable position of having the opportunity to evaluate multiple potential sales and marketing partners in markets to ensure that these companies have the required capabilities to effectively sell and market Altrazeal® and maximize its long-term market potential. We have now completed agreements for two territories in the EU with product launches projected for summer 2013. Furthermore, we anticipate conclusion of additional agreements for 4 – 5 mor
'/>"/>
| SOURCE ULURU Inc. Copyright©2012 PR Newswire. All rights reserved |
Related medicine technology :
1. ULURU Inc. Announces Closing Of $440,000 Private Placement
2. ULURU Inc. Reports Third Quarter 2012 Financial Results
3. ULURU Inc. Announces The First Shipment Of Veterinary Product
4. ULURU Inc. Announces First Order Of Altrazeal For European Launch
5. ULURU Inc. Reports Second Quarter 2012 Financial Results
6. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
7. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
8. PCMA: New Report Shows Anti-PBM Laws Could Raise Health Care Costs for Oklahoma Businesses, Consumers, Government Programs
9. Sentrys Business Intelligence Platform is Prepared for 340B GPO Policy Update Requirements
10. Medbox CEO Scheduled to Appear on Fox Business Channel
11. ScanMed QR Wins Cox Business and Inc. Magazine "Get Started OKC" Pitch Contest
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013 Medical devices are ... a biological product. In light of their different mechanisms, ... are much more complicated than drug trails due to ... MD safety instead of evaluating both safety and efficacy ... FDA (which is the same as the SFDA) evaluate ...
(Date:5/17/2013)... SAN DIEGO and CAMBRIDGE, Mass., May 17, 2013 ... announce that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: ... District Court for the District of Massachusetts ... of its officers violated the Securities Exchange Act of ... May 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2... Eli Lilly and Company,(NYSE: LLY ) ... with the,European Medicines Agency (EMEA) for centralised review ... for the,first-line treatment of advanced non-small cell lung ... more than 85 countries as a,second-line, single agent ...
... insulin glargine, exenatide offered added benefits of, ... with metformin --, AMSTERDAM, Netherlands, Sept. 21 ... Eli Lilly and Company (NYSE: LLY ),today ... insulin glargine on beta-cell function, glycemic control and ...
Cached Medicine Technology:Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 2Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 3Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 4Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 5Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 6Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 7Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 8Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 9Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 10Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 11Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 12One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 2One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 3One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 4One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 5One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 6One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 7(Date:5/20/2013)... of Southampton has shown that blind and visually impaired ... that used by bats and dolphins, to determine the ... published in the journal Hearing Research , examined ... help blind people with spatial awareness and navigation. The ... and how to optimise echolocation ability in order to ...
(Date:5/20/2013)... Selexis SA, a serial innovation company ... line development for scale-up and manufacturing of therapeutic protein ... data on the Company’s core technology at the 2013 ... 20 - 23 at the Hyatt Regency La Jolla ... scientific advisory board member, Nicolas Mermod, PhD, Professor of ...
(Date:5/20/2013)... The International Distance Skateboard Association has elected ... the best long distance skaters to attend and compete. This ... venue of raising money for our local Boys & Girls ... is the authority on long distance races throughout the world ... is safe and organized for all who want to attend ...
(Date:5/20/2013)... 20, 2013 Gilman Law LLP, a ... investigating Byetta lawsuits, is troubled by a new study ... and similar type 2 diabetes drugs are growing. ... Practices (ISMP), found that 71 Byetta pancreatic cancer reports ... Administration (FDA) as of June 30, 2012. ...
(Date:5/20/2013)... OH (PRWEB) May 20, 2013 Humidifiers.com ... Form that will satisfy all summer home indoor air ... to carry Stadler Form products that will keep homes ... offers several elegant products designed specifically for the warm ... from Stadler Form are available: Otto and Charly. ...
Breaking Medicine News(10 mins):Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 3Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3Health News:Humidifiers.com has Now Extended their Summer Line with the Sleek, Modern Product Line, Stadler Form 2[0] New study finds blind people have the potential to use their 'inner bat' to locate objects[0] Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering[0] Skateboard Marathon Race in Tradition - July 20th, Big Race, Big Fun, Big Attraction, Big Event for a Big Cause[0] Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports[0] Humidifiers.com has Now Extended their Summer Line with the Sleek, Modern Product Line, Stadler Form
... Warwick Medical School found that premature babies face a greater ... included 120,000 children born between 1983 and 2001. The findings ... and were born premature are more often placed on the ... were born before 34 weeks. The findings were penned down ...
... Siteman Cancer Center are a part of the new ... Medicine's Medical Photography, Illustration and Computer Graphics (MedPIC) department. ... and their families to paint a 4-inch square ceramic ... have been painted in this manner. These unique artworks ...
... for a appointment a local clinic now you can take ... 10 minutes//, ,Chlamydia is the most common sexually transmitted ... can be passed on to others without knowing. However, complications ... pregnancy and infertility in both men and women., ,The ...
... group jogging or jogging with a friend will be more ... ,Researchers led by Professor Elizabeth Gould at Harvard University compared ... exercise in a group and found that contrary to accepted ... reported online edition of Daily Mail. ,The researchers ...
... the kingdom was untouched by the avian flu disease. // ... of both the public and the government. He said that there ... , The minister made the remarks during a ... that occasion to celebrate this great achievement the people were served ...
... in the majority of the cases is caused by viral ... could be prevented by vaccination. // Cancer of cervix, liver, ... leukemia are thought to be caused by viruses. Stomach cancer ... Campaign said that viruses can trigger the disease in combination ...
Cached Medicine News:Health News:Home Chlamydia Test 2Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |